NCT05268341 Neuroimaging Reveals Treatment-related Changes in DLD
| NCT ID | NCT05268341 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Cincinnati |
| Condition | Developmental Language Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-05-24 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2022-05-24 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Children with developmental language disorders (DLD, aka specific language impairment), a prevalent pediatric disorder, experience hallmark grammar deficits with life-long impacts on educational and occupational outcomes. While effective and early interventions can mitigate the impact of DLD, not enough is known about the neural basis of DLD in young children, yet is needed to inform the design of more individualized interventions. This project uses neuroimaging, along with behavioral methods, with the goal of better understanding the memory-language mechanisms that underlie grammar learning and impairment, while also considering their association to treatment-related changes in preschoolers with DLD.
Eligibility Criteria
Inclusion Criteria: * ages 48-71 months * average nonverbal intelligence quotient (IQ) * enrolled in participating center * typically developing (receptive and expressive language, social, articulation, other) * DLD for expressive grammar * typical oral motor function * typical social/pragmatics skills * average hearing thresholds * monolingual and native Standard English speakers * does not have any uncorrected vision challenges Exclusion Criteria: * receiving co-occurring speech-language or other intervention for communication * not MRI safe * special education placement of child based on ability or behavior
Contact & Investigator
Karla N Washington, PhD
PRINCIPAL INVESTIGATOR
University of Cincinnati
Frequently Asked Questions
Who can join the NCT05268341 clinical trial?
This trial is open to participants of all sexes, aged 48 Months or older, up to 71 Months, studying Developmental Language Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05268341 currently recruiting?
Yes, NCT05268341 is actively recruiting participants. Contact the research team at washink2@ucmail.uc.edu for enrollment information.
Where is the NCT05268341 trial being conducted?
This trial is being conducted at Cincinati, United States, Cincinnati, United States, Cincinnati, United States, Cincinnati, United States and 2 additional locations.
Who is sponsoring the NCT05268341 clinical trial?
NCT05268341 is sponsored by University of Cincinnati. The principal investigator is Karla N Washington, PhD at University of Cincinnati. The trial plans to enroll 100 participants.